Subsection 5: Special provisions for systemic medicinal treatments for cancer

Articles in this section · 4

R6123-94R6123-94-1R6123-94-1-1R6123-94-2

Article R6123-94

French Public Health CodeIn force
Ask for lawyer reviewed or certified translation

Updated 1 Nov 2023

I-Treatment of cancer by systemic medicinal treatments for cancer consists, within the authorised site :

1° The development of a therapeutic proposal in a multidisciplinary consultation meeting, following the initial diagnosis but also on the occasion of reassessment assessments;

2° The therapeutic decision on systemic cancer drug treatment, regardless of the method of administration, taken during a one-to-one interview by a prescribing doctor, as well as any decision, taken under the same conditions, to make significant changes to this treatment during the patient's episode of care linked to a change of molecules or the extension of treatment. These therapeutic decisions or significant changes consist of the initial prescription of systemic cancer drug treatment for the patient, in compliance with the provisions of 1° of article R. 6123-91-1;

3° Carrying out systemic cancer drug treatment. In the case of oral medicinal treatments dispensed in dispensing pharmacies and taken by the patient at home, the holder has an organisation for liaising with dispensing pharmacies to support the patient throughout his treatment;

4° For holders of the B and C grades, the management of foreseeable aplasia lasting more than eight days induced by intensive chemotherapy;

5° Patient follow-up during treatment and after the episode of systemic cancer drug treatment.

II-Per derogation to I, the holder of the authorisation for systemic medicinal treatments for cancer may, within the framework of its agreement or its formalised organisation with an associated establishment established under the conditions provided for in II of article R. 6123-90-1, provide for an organisation that allows decisions to be made to significantly change systemic cancer drug treatments on the site of the associated establishment, for patients already referred by it and on condition that these significant changes in treatment are carried out as part of an advanced consultation or teleconsultation with a member of the team of the holder of the authorisation for systemic cancer drug treatments.

Mariela Petrova

Need help applying this article to your situation?

A registered French Lawyer explains what applies to your business — in English, fixed fee.

within 48h

Fixed Fee

Talk to a lawyer
Previous articleArticle R6123-93-7Next articleArticle R6123-94-1
Common Questions

Working with a corporate lawyer in France — Q&A

Any time a strategic decision changes how the company is owned, governed or contractually bound — incorporation, fundraising, M&A, restructuring, shareholder agreements, or major commercial contracts. Earlier engagement always costs less than later remediation.

A notary (notaire) is a public officer who authenticates specific deeds (mainly real-estate transfers and certain family-law acts). A corporate lawyer (avocat) advises on strategy, negotiates and drafts company documents, and represents you in disputes. The two roles complement rather than overlap.

Yes — most of our clients are foreign suppliers, investors or holding entities. We bridge the gap between French law and your home jurisdiction's expectations and deliver everything bilingually.

The SAS (Société par Actions Simplifiée) is the default choice for most international structures: flexible governance, single shareholder allowed, no minimum capital, and works cleanly with foreign holding entities. We assess SARL, SA, SCI on the merits when the situation calls for it.

Yes — communications with a French avocat are protected by the secret professionnel (Article 66-5 of the Law of 31 December 1971). This protection is broader than the common-law attorney-client privilege and applies to written and oral exchanges.

We work on fixed fees for clearly scoped engagements (incorporation, contract drafting, audits) and on monthly retainers for ongoing advisory. Hourly billing is the exception, not the default. You always know the cost before work starts.

Typical timeline is 2–3 weeks from KYC kick-off to RCS registration, assuming standard documentation. Holding-company structures, foreign-shareholder identification or in-kind contributions can extend this — we flag the gating items at the first meeting.

Absolutely. We routinely coordinate with your in-house counsel, expert-comptable or notaire — pragmatic collaboration is the norm, not the exception. We send them everything they need to do their part without duplicating work.

Mariela Petrova

Mariela Petrova

Avocate au Barreau de Paris

Toque #C2396

15+ Years In Corporate Practice

English · French · Russian

Ready When You Are

Talk To A Corporate
Lawyer In France.

A 20–30 minute call, in English, to scope the engagement. No obligation, no preliminary fee. You will leave the call with a clear view of what the work will cover and what it will cost.

Talk To A Corporate Lawyer+33 1 84 88 31 00
First EngagementFixed Fee

Talk to a French lawyer.

Reply within 24 hours.

Communications protected by professional secrecy — secret professionnel de l'avocat, Article 66-5 of the Law of 31 December 1971.

Continue Reading

Related corporate services in France

01 / Setup

Setting up a French company

Choose between SAS, SARL, SA or SCI — and structure your first French entity around how you actually plan to operate.

Read More
02 / Operating

French commercial contracts

Distribution, agency, supply, services and IP licences — drafted around the protections French law actually gives.

Read More
03 / Disputes

Business disputes & litigation

Shareholder conflicts, commercial breaches and pre-litigation strategy — handled by the same team that knows the file.

Read More